Bausch + Lomb HomeExternal link
Treatment of Postoperative Treatment of Postoperative
 

Treatment of Postoperative Cystoid Macular Edema Associated with Posterior Uveitis test

Danny Mammo, MD

Download
Treatment of Cystoid Treatment of Cystoid
 

Treatment of Cystoid Macular Edema and Focal Chorioretinal Inflammation Associated With Chronic Idiopathic Uveitis

Lana Rifkin, MD

Download
Treatment of Macular Treatment of Macular
 

Treatment of Macular Edema Associated With Uveitis in a Phakic Patient With Sarcoidosis

Veena Raiji, MD

Download
Treatment of Postsurgical Cystoid Macular Treatment of Postsurgical Cystoid Macular
 

Treatment of Postsurgical Cystoid Macular Edema in a Patient With Reactivation of Panuveitis Following Implantation of a Scleral Fixated IOL

Robert Wang, MD

Download
An In-Depth Discussion An In-Depth Discussion
 

An In-Depth Discussion on the Appropriate Patient Type for XIPERE® InXights

Stephen Anesi, MD; Peter Chang, MD; Mark Dacey, MD; Yasha Modi, MD; Veena Raiji, MD; Eduardo Uchiyama, MD; Scott Walter, MD; Robert Wang, MD

Download
An In-Depth Discussion An In-Depth Discussion
 

An In-Depth Discussion on the Appropriate Patient Type for XIPERE® InXights

Stephen Anesi, MD; Peter Chang, MD; Mark Dacey, MD; Yasha Modi, MD; Veena Raiji, MD; Eduardo Uchiyama, MD; Scott Walter, MD; Robert Wang, MD

Download
An In-Depth Discussion An In-Depth Discussion
 

An In-Depth Discussion on the Appropriate Patient Type for XIPERE® InXights

Stephen Anesi, MD; Peter Chang, MD; Mark Dacey, MD; Yasha Modi, MD; Veena Raiji, MD; Eduardo Uchiyama, MD; Scott Walter, MD; Robert Wang, MD

Download

Indication

XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Important Safety Information

Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.

  • XIPERE® is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
  • XIPERE® is contraindicated in patients with known hypersensitivity to triamcinolone acetonide or any other components of this product.
  • Use of corticosteroids may produce cataracts, increased intraocular pressure, and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses, and should be used cautiously in patients with a history of ocular herpes simplex.
  • Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and hyperglycemia can occur following administration of a corticosteroid. Monitor patients for these conditions with chronic use.
  • In controlled studies, the most common ocular adverse reactions were increased ocular pressure, non-acute (14%), eye pain, non-acute (12%), cataract (7%), increased intraocular pressure, acute (6%), vitreous detachment (5%), injection site pain (4%), conjunctival hemorrhage (4%), visual acuity reduced (4%), dry eye (3%), eye pain, acute (3%), photophobia (3%), and vitreous floaters (3%), and in 2% of patients: uveitis, conjunctival hyperaemia, punctate keratitis, conjunctival oedema, meibomianitis, anterior capsule contraction, chalazion, eye irritation, eye pruritus, eyelid ptosis, photopsia, and vision blurred.
    The most common non-ocular adverse event was headache (5%).
  • Corticosteroids should be used during pregnancy or nursing only if the potential benefit justifies the potential risk to the fetus or nursing infant.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information.

See More

Indication

XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Important Safety Information

Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.

  • XIPERE® is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
  • XIPERE® is contraindicated in patients with known hypersensitivity to triamcinolone acetonide or any other components of this product.